Prevalence and risk factors associated with resistance-associated mutations to etravirine in a cohort of perinatally HIV-infected children | Zendy

German Contreras | Zendy; Cynthia Bell | Zendy; Gabriela Del Bianco | Zendy; Norma Pérez | Zendy; Matthew Kleinosky | Zendy; James R. Murphy | Zendy; Gloria P. Heresi | Zendy

Open Access

Prevalence and risk factors associated with resistance-associated mutations to etravirine in a cohort of perinatally HIV-infected children

Author(s) -

German Contreras,

Cynthia Bell,

Gabriela Del Bianco,

Norma Pérez,

Matthew Kleinosky,

James R. Murphy,

Gloria P. Heresi

Publication year - 2013

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkt198

Subject(s) - etravirine , cohort , human immunodeficiency virus (hiv) , virology , medicine , cohort study , sida , biology , viral disease , pediatrics , antiretroviral therapy , viral load

Etravirine is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) with reduced cross-resistance to first-generation NNRTIs. Because many perinatally HIV-infected patients have been treated with first-generation NNRTIs, they may have acquired resistance-associated mutations to etravirine (RAMe).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research